How big is the Human Insulin Drugs Market?

The Human Insulin Drugs Market size is expected to reach USD 27.96 billion in 2024 and grow at a CAGR of 3.87% to reach USD 33.81 billion by 2029. Read More

What is the current Human Insulin Drugs Market size?

In 2024, the Human Insulin Drugs Market size is expected to reach USD 27.96 billion. Read More

Who are the key players in Human Insulin Drugs Market?

Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Biocon Limited and Pfizer Inc. are the major companies operating in the Human Insulin Drugs Market. Read More

Which is the fastest growing region in Human Insulin Drugs Market?

North America is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Human Insulin Drugs Market?

In 2024, the North America accounts for the largest market share in Human Insulin Drugs Market. Read More

What years does this Human Insulin Drugs Market cover, and what was the market size in 2023?

In 2023, the Human Insulin Drugs Market size was estimated at USD 26.88 billion. The report covers the Human Insulin Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Human Insulin Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

What are the key factors driving the Insulin Market?

The key trends in the insulin market are a) Diabetes Prevalence: Diabetes numbers are rising due to factors like obesity and unhealthy diets b) Aging Population: As the population ages, the risk of diabetes increases, leading to a greater demand for insulin c) Diabetes Awareness: Growing awareness about diabetes and its risks leads to more diagnoses and treatments, including insulin. Read More

Human Insulin Drugs Market Growth | Industry Analysis, Size & Forecast Report

Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Global Insulin Market is Segmented by Product Type (traditional Human Insulins, Basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Insulin Combinations, and Biosimilar Insulins), Type ( Hospital/Clinics, Home/Personal) and Geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Insulin Industry Overview

The global human insulin market is highly consolidated, with three major manufacturers holding a global market presence and the remaining manufacturers confined to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Basaglar (Insulin Glargine). Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. Fast-acting oral insulin could improve postprandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus providing a more convenient, effective, and safer method for delivering insulin therapy.